CoChat

Cohort profile: the Asia Pacific Cohort Studies Collaboration

Open access
Woodward, M, Barzi, F, Martiniuk, A, Fang, X, Gu, DF, Imai, Y, Lam, TH, Pan, WH, Rodgers, A, Suh, I, Jee, SH, Ueshima, H, Huxley, R · 2006 · International Journal of Epidemiology
Cited by 86

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Abstract

Although less well recognized than in the West, cardiovascular disease (CVD) is the leading cause of disease in Asia. This is despite known differences in the distribution of risk factors for CVD in Asia, compared with Europe and North America, such as lower average total cholesterol and body mass index (BMI). The nature of CVD also tends to be different in Asia, where there are more strokes than coronary heart disease (CHD) events, and strokes are more often haemorrhagic than ischaemic, compared with the West. By 1999 the knowledge gap in Asia was a clear impediment to progress in treating and preventing CVD in the continent. Most of the existing studies from Asia were of small size or short duration and, thus, could not provide reliable information as to the way risk factors, well-researched in the West, act upon CVD in Asia. A notable exception was the Eastern Stroke and CHD Collaborative Project,1 which had studied the effects of diastolic blood pressure and total cholesterol on the risk of stroke and coronary disease in China and Japan. This was the starting point for the Asia Pacific Cohort Studies Collaboration (APCSC),2 which extended the scope of the Eastern Project in several important ways. APCSC covers a wider geographical area, including studies from Australia and New Zealand (ANZ), which provide a ‘Western’ comparison group, as well as increasing numbers for certain pooled analyses. It uses individual participant, rather than summary, data, which allows for more flexible analyses. Also, it collects data on several risk factors for CVD, not just blood pressure and total cholesterol, and records all deaths, including those due to non-cardiovascular causes. Initial funding was provided by the New Zealand Health Research Council and the Australian National Health and Medical Research Council (NHMRC). Twin Secretariats for APCSC were established at the Clinical Trials Research Unit at the University of Auckland, New Zealand and The George Institute for International Health at the University of Sydney, Australia. In later years, Pfizer Inc. of New York provided two substantial unrestricted educational grants to APCSC. Current funding is a mixture of pharmaceutical industry funding (Pfizer), peer reviewed research council funding (NHMRC; through a programme grant), and university funding (a University of Sydney cancer research award). The Secretariat and database are now solely housed within The George Institute. The primary aims of APCSC are to determine the age-specific, sex-specific, and region-specific (Asia and ANZ) associations of major cardiovascular risk factors with stroke (fatal and non-fatal, ischaemic and haemorrhagic), CHD (fatal and non-fatal), total CVD. Secondary outcomes are all-cause mortality and other major causes of death (e.g. cancer). The primary analytical method is to use Cox proportional hazard regression models, adjusted for age and stratified by study (and where appropriate, sex) to calculate hazard ratios and confidence intervals. Continuous variables are adjusted for regression dilution error.2 Studies are eligible for inclusion in APCSC if they are based in the Asia Pacific region, use a cohort study design, and have at least 5000 person-years of follow-up. Individuals within each study are included if they have recordings, at baseline, of date of birth (or age), sex and blood pressure, and have vital status known at the end of follow-up, together with date of death (or the age at death) where applicable. Cohorts selected on the basis of a positive disease history, or diagnosis, are excluded. Studies were identified by a range of methods, including searches of electronic databases (MEDLINE and EMBASE), scrutiny of abstracts and proceedings of meetings, and by personal enquiry among collaborators and colleagues. For each identified eligible study, the principal investigators (PIs) were invited to participate. Figure 1 shows the distribution of studies included in the APCSC database at the time of the third datalock, in April 2006 (previous datalocks were in 2000 and 2003). Study names, and names of PIs, are given in the acknowledgements; this includes two studies that have agreed to join APCSC but have yet to qualify according to the entry criteria. The studies in Figure 1 are the only ones included in the remainder of this article. Map showing studies in the Asia Pacific Cohort Studies Collaboration APCSC studies are free to contribute whatever data they like to the Collaboration. Of the 44 studies, 28 have only provided baseline data; 16 have additionally provided data on one repeat enumeration and six have contributed more than one repeat set of measurements, up to a maximum of seven repeats. The median follow-up is 6.7 years and the longest follow-up of any individual, not yet deceased, is 36 years. As the primary outcomes in this collaboration are cardiovascular, the baseline risk factors collected are all the well-established risk factors for CVD. Table 1 gives a l

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/ije/dyl222

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 86

Metadata

Authors
Woodward, M., Barzi, F., Martiniuk, A., Fang, X., Gu, D., Imai, Y., Lam, T., Pan, W., Rodgers, A., Suh, I., Jee, S., Ueshima, H., & Huxley, R.
Venue
International Journal of Epidemiology
Published
2006-10-22
Volume
35
Issue
6
Pages
1412-1416
ISSN
  • 0300-5771 (ISSN-L)
  • 1464-3685
OpenAlex
W2170105848
Cited by
86
References
3
FWCI
4.59
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.